Recursion Pharmaceuticals Inc
RXRX5.030USD
-0.370-6.85%
收盤 06/27, 16:00（美東）報價延遲15分鐘
2.04B總市值
虧損本益比TTM
關於 Recursion Pharmaceuticals Inc 公司
Recursion Pharmaceuticals, Inc. 是一家臨牀階段的 TechBio 公司，致力於解碼生物學，實現藥物研發的工業化。其 Recursion 操作系統 (OS) 是一個跨多種技術構建的平臺，使公司能夠映射和導航 Recursion 數據宇宙中的數萬億生物和化學關係。該公司將物理和數字組件集成爲原子和比特的迭代循環，將溼實驗室生物學和化學數據組織成良性循環，並使用計算工具將計算機假設快速轉化爲經過驗證的見解和新穎的化學反應。其臨牀項目包括 REC-994、REC-2282、REC-4881 和 REC-3964。REC-994 是一種口服生物可利用的超氧化物清除劑小分子，正在開發用於治療有症狀的腦海綿狀畸形 (CCM)。 REC-2282 用於潛在治療 2 型神經纖維瘤病。REC-3964 用於預防複發性艱難梭菌感染。
公司簡介
公司代碼RXRX
公司名稱Recursion Pharmaceuticals Inc
上市日期Apr 16, 2021
成立日期2013
CEODr. Christopher Gibson, Ph.D.
員工數量840
證券類型Ordinary Share
年結日Apr 16
公司地址41S Rio Grande Street
城市SALT LAKE CITY
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編84101
電話13852690203
網址https://www.recursion.com/
公司代碼RXRX
上市日期Apr 16, 2021
成立日期2013
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.19M
+0.69%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
142.54K
-20.25%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
132.89K
+19.86%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
Director, Chief Research and Development Officer, Chief Commercial Officer
Director, Chief Research and Development Officer, Chief Commercial Officer
14.63K
-20.60%
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.19M
+0.69%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
142.54K
-20.25%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
132.89K
+19.86%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月28日 週三
更新時間: 5月28日 週三
持股股東
股東類型
持股股東
持股股東
佔比
ARK Investment Management LLC
8.71%
The Vanguard Group, Inc.
8.06%
Baillie Gifford & Co.
6.10%
BlackRock Institutional Trust Company, N.A.
5.02%
SB Global Advisers Ltd
3.67%
Other
68.43%
持股股東
持股股東
佔比
ARK Investment Management LLC
8.71%
The Vanguard Group, Inc.
8.06%
Baillie Gifford & Co.
6.10%
BlackRock Institutional Trust Company, N.A.
5.02%
SB Global Advisers Ltd
3.67%
Other
68.43%
股東類型
持股股東
佔比
Investment Advisor
36.58%
Investment Advisor/Hedge Fund
19.62%
Venture Capital
8.74%
Sovereign Wealth Fund
4.12%
Individual Investor
3.17%
Research Firm
2.16%
Hedge Fund
2.01%
Corporation
1.93%
Bank and Trust
0.86%
Other
20.83%
機構持股
更新時間: 3月4日 週二
更新時間: 3月4日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
637
324.02M
81.93%
+29.39M
2024Q4
611
317.29M
80.77%
+25.35M
2024Q3
560
281.65M
104.01%
-6.72M
2024Q2
527
272.94M
105.41%
+14.66M
2024Q1
478
234.97M
104.72%
-10.28M
2023Q4
433
227.80M
110.74%
+18.50M
2023Q3
402
195.18M
97.47%
+1.19M
2023Q2
358
172.49M
89.73%
-20.74M
2023Q1
345
171.25M
93.19%
-16.02M
2022Q4
321
167.85M
92.66%
-946.19K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
ARK Investment Management LLC
32.35M
8.19%
-422.79K
-1.29%
Dec 31, 2024
The Vanguard Group, Inc.
33.97M
8.6%
+9.74M
+40.18%
Dec 31, 2024
Baillie Gifford & Co.
24.86M
6.29%
-375.81K
-1.49%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
20.31M
5.14%
+2.56M
+14.39%
Dec 31, 2024
SB Global Advisers Ltd
14.67M
3.71%
+14.67M
--
Dec 31, 2024
Kinnevik AB
11.91M
3.01%
--
--
Dec 31, 2024
State Street Global Advisors (US)
12.58M
3.18%
-291.91K
-2.27%
Dec 31, 2024
Mubadala Investment Company PJSC
12.99M
3.29%
--
--
Dec 31, 2024
DCVC Management Co, LLC
5.94M
1.5%
-3.73M
-38.55%
Dec 31, 2024
Novo Holdings A/S
10.11M
2.56%
+10.11M
--
Dec 31, 2024
查看更多
持股ETF
更新時間: 6月6日 週五
更新時間: 6月6日 週五
機構名稱
佔比
ARK Genomic Revolution ETF
4.95%
ARK Innovation ETF
1.5%
First Trust Nasdaq AI and Robotics ETF
1.01%
AXS Green Alpha ETF
0.81%
Franklin Genomic Advancements ETF
0.66%
WisdomTree BioRevolution Fund
0.64%
Main Thematic Innovation ETF
0.59%
SPDR S&P Biotech ETF
0.56%
Virtus LifeSci Biotech Clinical Trials ETF
0.45%
Direxion Daily S&P Biotech Bull 3X Shares
0.37%
查看更多
ARK Genomic Revolution ETF
佔比4.95%
ARK Innovation ETF
佔比1.5%
First Trust Nasdaq AI and Robotics ETF
佔比1.01%
AXS Green Alpha ETF
佔比0.81%
Franklin Genomic Advancements ETF
佔比0.66%
WisdomTree BioRevolution Fund
佔比0.64%
Main Thematic Innovation ETF
佔比0.59%
SPDR S&P Biotech ETF
佔比0.56%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.45%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.37%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
